1
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Biallelic mutations in UGDH cause congenital microcephaly

      brief-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hengel et al recently reported that bi-allelic loss-of-function mutations in UDP-Glucose 6-Dehydrogenase (UGDH) caused a severe epileptic encephalopathy syndrome-Jamuar syndrome (OMIM #618792). 1 The functional studies partially recapitulated the clinical phenotypes in the patient-derived cerebral organoid. A reduced number of proliferating neuronal progenitors in cerebral organoids was shown, which is a critical mechanism in congenital microcephaly (CM) whose patients were born with an occipitofrontal circumference (OCF) more than 2 standard deviations below average for age and sex. However, none of the reported patients in the article presented the phenotype as CM. Here, we first identified UGDH compound heterozygous mutations (chr4:39523062-39523062 NM_003359.3:c.71C > T:p.A24V; chr4:39512342-39512342 NM_003359.3:c.404G > A:p.R135Q) in one family with CM by exome sequencing (ES) and Sanger validation. We then screened the Chigene database in China for additional CM patients with recessive UGDH mutations. Another patient with CM who also carried UGDH compound heterozygous mutations (chr4:39511460-39511460 NM_003359.3: c.731C > A: p.T244K; chr4:39515798-39515798 NM_003359.3: c.169C > A: p.L57I) was identified (Fig. 1A, B; Fig. S1). Figure 1 Compound heterozygous mutations in the UGDH gene caused decreased enzymatic activity, interruption of the cell cycle, small brain and neuronal loss in zebrafish F0 crispant. (A) The pedigree of family 1 segregates CM. The arrow points to the proband. Compound heterozygous mutations c.71C > T and c.404G > A in UGDH are presented below individuals. (B) The pedigree of the family 2 segregates CM. The arrow points to the proband.Compound heterozygous mutations c.169C > A and c.731C > A in UGDH are presented below individuals. (C, D) Purified UGDH wild-type (WT) and mutant enzymatic activity. (C) A24V and R135Q in patient 1 and (D) L57I and T244K in patient 2 were measured as the turnover of NAD+ to NADH. The assay was performed by at least three replicate experiments. (E) Percentage of cells in different phases of the cell cycle (G0/G1, S, G2/M). KD, UGDH knockdown HEK293 cell. Ctrl, controls. ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001; student's t-test. ns indicates no significance with a P-value >0.05. (F) Representative bright-field imaging of larval zebrafish at 5 days after fertilization (dorsal view). Top, cas9 injected control; bottom, ugdh F0 CRISPR (crispant). The Red plus blue line indicates the body length and the red line indicates the head length. (G) Representative imaging of HuC: eGFP-expressed larval zebrafish shows CNS fluorescence pattern at 5 after fertilization (dorsal view). Left, cas9 injected control; right, ugdh crispant. (H–J) Measurements of body length, head length, and the head-to-body length ratio in cas9 injected control (n = 20 fish) versus ugdh crispant (n = 28 fish). Body length and head length data were normalized to the mean value of cas9 control group. (K) Normalized CNS fluorescence area in cas9 injected control (n = 20 fish) versus ugdh crispant (n = 28 fish). Scale bars are indicated in the figure. Error bars indicate standard deviation (SD). Statistical significance is indicated as ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001. Fig. 1 Patient 1 showed typical CM with progressively reduced OCF in pregnancy and OCF of 30.5 cm at 40 weeks of birth. He also showed core features of Jamuar syndrome by presenting developmental delay, severe refractory epilepsy-infantile spasms, and hypotonia accompanied by facial dysmorphisms such as flattened philtrum. Patient 2 also showed typical CM with OCF of 29.0 cm at 39 weeks of birth. He showed refractory epilepsy and severe developmental delay. Hypotonia was also detected. Magnetic resonance images (MRI) of the brain in both patients were normal. These UGDH missense mutations were predicted to be likely pathogenic and highly conserved by multiple in silico tools (Table S1). The four variants are absent from normal population databases such as GnomAD, ExAC, and 1000genomes. The protein structure prediction (Fig. S2, 3A, B) showed that the angles and distances between UGDH mutants and the contact atoms were different from wild-type UGDH. For p.T244K mutant, one of the interaction molecules has changed from A246 to K465 (Fig. S3B). These may indicate that UGDH mutants could lead to altered local structure, thus affecting UGDH enzyme functions. UGDH enzymatic activity was further measured by the activity of NADH oxidase assay accompanied with trypsin susceptibility assay and thermal stability measurement. As shown in Fig. 1C, we found that the efficiency of conversion of NAD+ to NADH was reduced when comparing UGDH A24V and R135Q (Patient 1) group with UGDH WT group (62% (P < 0.0001) and 39% (P < 0.0005)). For patient 2 with UGDH L57I and T244K (Fig. 1D), the reduction in efficiency of conversion of NAD+ to NADH as compared to UGDH WT were 46% (P < 0.0005) and 55% (P < 0.0001) respectively. We further found that the UGDH missense mutations may reduce the enzymatic oxidoreductive activity by affecting its sensitivity to proteolysis and/or thermal stability (Fig. S2, 3C, D). These results suggested a loss-of-function mechanism underlying UGDH missense mutations. Therefore, we constructed UGDH knockout HEK293T cell models to elucidate the pathogenesis of UGDH. In order to explore the key proteins or pathways regulated by UGDH mutations, TMT labeled quantitative proteomic analysis on UGDH knockout and wild-type HEK293T cells was applied. A total of 7,772 proteins were identified, out of which the number of quantifiable proteins was 7,769. Taking the fold change (FC) > 1.2 times (up-regulation greater than 1.2 times or down-regulation less than 0.83 times) and P-value < 0.05 as the standard, the number of up-regulated and down-regulated proteins between groups was 575 and 535, respectively (Fig. S4A). Gene ontology analysis of biological processes showed that the differentially expressed protein may be enriched in functional categories including cell proliferation, developmental process, etc (Fig. S4B). The Kyoto Encyclopedia of Genes and Genomes pathway analysis showed that the differentially expressed protein was enriched in the cell cycle pathway etc (Fig. S4C). In accordance with the proteomic analysis, cell cycle analysis showed that the loss of function of UGDH resulted in the interruption of the cell cycle transition from the G1 to the S phase. We used UGDH knockdown HEK293 cell models and found that there were about 9% more cells in the G1 phase and about 9% fewer cells in the S phase in the gene knockdown group than in the control group (P < 0.05). However, the percentage of cells in G2/M between the two groups has no statistically significant difference (Fig. 1E). To further evaluate the function of UGDH in brain development, we obtained RNA sequencing data from BrainSpan. The Spatio-temporal expression pattern of UGDH suggested that there is a time-dependent down-regulation of UGDH expression in the fetal brain and in the postnatal brain. The high expression level was observed in fetal periods in most brain regions (Fig. S5A, B). The result implicated a major role of UGDH in brain development during embryonic development periods. In the zebrafish model, significant differences of head length, body length, head-to-body length ratio, and central nervous system fluorescence area were observed between cas9 injected control and ugdh first generation (F0) crispant (P < 0.01, 0.001, 0.001, 0.001, respectively) (Fig. 1F–K). The F0 crispant simulated CM by showing small brain and neuronal loss. UGDH (MIM603370) is a vital enzyme that catalyzes UDP-glucose to UDP-glucuronate accompanied by NAD+ to NADH. Its downstream product-the extracellular matrix glycosaminoglycan component hyaluronan is essential for multiple cell functions. 2 As a crucial gene functioning in the neurological system, UGDH mutations were first proved to be causative to developmental and epileptic encephalopathy 84-Jamuar syndrome by Hengel et al in 2020. 1 The zebrafish model developed by the author did not phenocopy the clinical features of the phenotypes of patients satisfactorily by only simulating the motor developmental delay. Additionally, Hengel et al found a reduced volume of patient-derived cerebral organoids due to decreased number of neuroprogenitors (NPCs). Not only does the finding indicate the importance of UGDH in neurodevelopment, but it also coincided with the core pathogenesis underlying CM. The CM phenotype was not shown in the patients reported by Hengel et al. Fortunately, we identified two patients with CM accompanied by developmental delay and refractory seizures who harbored UGDH compound heterozygous mutations, therefore, to make the clinical presentations of patients more congruent with functional studies. The protein structure prediction indicated that the protein stability and enzymatic function were affected by UGDH mutations. The angles, distances, and interaction molecules were changed by UGDH mutations which could result in impaired enzyme functions and downstream products. In accordance with the structure prediction, the lower level of UGDH enzyme activities caused by UGDH missense mutations also indicated the loss-of-function mechanisms of these missense mutations. Furthermore, the quantitative proteomic analysis and UGDH knockdown cell models showed that the disturbed cell cycle may be the underlying mechanism in UGDH-related microcephaly. The bioinformatics analysis showed the importance of UGDH in brain development in embryonic development periods and ugdh F0 CRISPR (crispant) presented reduced brain volume and central nervous system (CNS) area. In accordance with patient-derived cerebral organoids in a previous study, which showed a markedly reduced number of NPCs and small volume, all supported the role of UGDH in CM pathogenesis. As a crucial gene-regulating proteoglycan (PG) and glycosaminoglycan (GAG) synthesis, UGDH is critical throughout cell development. It has been reported that in diverse organisms such as flies, worms, and plants, UGDH loss could result in limited developmental growth. For example, by interrupting downstream factors including Wnt, fibroblast growth factor, and transforming growth factor-β, phenotypes such as wing dysplasia in Drosophila were detected. 3 UGDH could implicate human diseases by affecting PG or GAG levels of the extracellular matrix and thus affecting tissue morphogenesis. 2 Inborn errors of proteoglycan metabolism could cause multiorgan impairments. So far, only three studies have reported UGDH-related congenital developmental diseases, including cardiac valve malformation and developmental, epileptic encephalopathy, and developmental delay. 1 , 4 , 5 Our study is the first report to unravel the role of UGDH in CM. Therefore, given the above data, together with the reduced number of NPCs in cerebral organoids presented by Hengel et al, we proposed that UGDH mutation is likely to cause CM. Author contributions XM and HW designed the research. LS wrote the manuscript. DQM provided information on one patient. RX performed the bioinformatic analysis. GYX, SXL, and XL collected and evaluated the clinical and genetic evidence. BX and YYX revised the manuscript. All authors read and approved the final manuscript. Conflict of interests All authors declare that there is no conflict of interests. Funding This work was supported by the Natural Science Foundation of Hunan Province, China (No. 2021JJ40280), the 10.13039/501100012166 National Key Research and Development Program of China (No. 2021YFC1005300), the Major Scientific and Technological Projects for Collaborative Prevention and Control of Birth Defects in Hunan Province, China (No. 2019SK1010, 2019SK1014), the National Key R&D Program of China (No. 2019YFC1005100), the 10.13039/501100002767 Hunan Provincial Science and Technology Department (China) (No. 2018SK2064), the Joint Construction Project of Henan Medical Science and Technology Project (China) (No. LHGJ20200618, 2018020633), and the Henan Engineering Research Center of Childhood Neurodevelopment Open Project (China) (No. SG201907).

          Related collections

          Most cited references5

          • Record: found
          • Abstract: found
          • Article: not found

          The Drosophila sugarless gene modulates Wingless signaling and encodes an enzyme involved in polysaccharide biosynthesis.

          We have identified and characterized a Drosophila gene, which we have named sugarless, that encodes a homologue of vertebrate UDP-glucose dehydrogenase. This enzyme is essential for the biosynthesis of various proteoglycans, and we find that in the absence of both maternal and zygotic activities of this gene, mutant embryos develop with segment polarity phenotypes reminiscent to loss of either Wingless or Hedgehog signaling. To analyze the function of Sugarless in cell-cell interaction processes, we have focused our analysis on its requirement for Wingless signaling in different tissues. We report that sugarless mutations impair signaling by Wingless, suggesting that proteoglycans contribute to the reception of Wingless. We demonstrate that overexpression of Wingless can bypass the requirement for sugarless, suggesting that proteoglycans modulate signaling by Wingless, possibly by limiting its diffusion and thereby facilitating the binding of Wingless to its receptor. We discuss the possibility that tissue-specific regulation of proteoglycans may be involved in regulating both Wingless short- or long-range effects.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Loss-of-function mutations in UDP-Glucose 6-Dehydrogenase cause recessive developmental epileptic encephalopathy

            Developmental epileptic encephalopathies are devastating disorders characterized by intractable epileptic seizures and developmental delay. Here, we report an allelic series of germline recessive mutations in UGDH in 36 cases from 25 families presenting with epileptic encephalopathy with developmental delay and hypotonia. UGDH encodes an oxidoreductase that converts UDP-glucose to UDP-glucuronic acid, a key component of specific proteoglycans and glycolipids. Consistent with being loss-of-function alleles, we show using patients’ primary fibroblasts and biochemical assays, that these mutations either impair UGDH stability, oligomerization, or enzymatic activity. In vitro, patient-derived cerebral organoids are smaller with a reduced number of proliferating neuronal progenitors while mutant ugdh zebrafish do not phenocopy the human disease. Our study defines UGDH as a key player for the production of extracellular matrix components that are essential for human brain development. Based on the incidence of variants observed, UGDH mutations are likely to be a frequent cause of recessive epileptic encephalopathy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Integration of Sugar Metabolism and Proteoglycan Synthesis by UDP-glucose Dehydrogenase.

              Regulation of proteoglycan and glycosaminoglycan synthesis is critical throughout development, and to maintain normal adult functions in wound healing and the immune system, among others. It has become increasingly clear that these processes are also under tight metabolic control and that availability of carbohydrate and amino acid metabolite precursors has a role in the control of proteoglycan and glycosaminoglycan turnover. The enzyme uridine diphosphate (UDP)-glucose dehydrogenase (UGDH) produces UDP-glucuronate, an essential precursor for new glycosaminoglycan synthesis that is tightly controlled at multiple levels. Here, we review the cellular mechanisms that regulate UGDH expression, discuss the structural features of the enzyme, and use the structures to provide a context for recent studies that link post-translational modifications and allosteric modulators of UGDH to its function in downstream pathways.
                Bookmark

                Author and article information

                Contributors
                Journal
                Genes Dis
                Genes Dis
                Genes & Diseases
                Chongqing Medical University
                2352-4820
                2352-3042
                11 January 2023
                September 2023
                11 January 2023
                : 10
                : 5
                : 1816-1819
                Affiliations
                [a ]National Health Commission Key Laboratory for Birth Defect Research and Prevention, Hunan Provincial Maternal and Child Health Care Hospital, Changsha, Hunan 410005, China
                [b ]Departments of Biochemistry, Molecular Biology and Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary T2N 4N1, Canada
                [c ]Alberta Children's Hospital Research Institute, University of Calgary, Calgary T2N 4N1, Canada
                [d ]Department of Neurology, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan 450018, China
                [e ]Department of Cell Biology and Genetics, School of Basic Medical Science, Xinjiang Medical University, Urumqi, Xinjiang 830054, China
                [f ]Department of Pediatric Neurological and Rehabilitation, Ganzhou Women and Children's Health Care Hospital, Ganzhou, Jiangxi 341000, China
                [g ]Department of Neurology, Xiangya Hospital, Changsha, Hunan 410005, China
                [h ]Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China
                [i ]Department of Medical Genetics, Hunan Provincial Maternal and Child Health Care Hospital, Changsha, Hunan 410005, China
                [j ]Clinical Research Center for Placental Medicine in Hunan Province, Hunan Provincial Maternal and Child Health Care Hospital, Changsha, Hunan 410005, China
                [k ]Department of Medical Genetics, Hunan Children's Hospital, Changsha, Hunan 410007, China
                Author notes
                []Corresponding author. wanghua_213@ 123456hotmail.com
                [∗∗ ]Corresponding author. National Health Commission Key Laboratory for Birth Defect Research and Prevention, Hunan Provincial Maternal and Child Health Care Hospital, Changsha, Hunan 410005, China. gbtechies@ 123456outlook.com
                [∗∗∗ ]Corresponding author. 55651829@ 123456qq.com
                [1]

                These authors have contributed equally to this work and are co-first authors.

                Article
                S2352-3042(23)00001-6
                10.1016/j.gendis.2022.12.007
                10363629
                a388dfbd-e4b9-451c-8135-50fadc3be0db
                © 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 18 April 2022
                : 8 November 2022
                : 1 December 2022
                Categories
                Rapid Communication

                Comments

                Comment on this article